in its filing to the exchanges on Thursday informed that the company has launched Ranolazine Extended-Release (ER) Tablets, 500mg and 1000mg in the US.
"Lupin's Ranolazine ER Tablets, 500mg, and 1,000mg are a generic version of Gilead Sciences, Inc.'s Ranexa ER Tablets, 500mg and 1,000mg. Ranolazine is indicated for the treatment of chronic angina," the company said in a press note to the exchanges on Thursday.
According to data released by IQVIA MAT in December 2018, Ranolazine ER Tablets, 500mg, and 1000mg had annual sales of ~$945mn in the US.
Lupin Ltd's share price is currently at Rs769.35, up by Rs1.65 or 0.21%, from its previous closing of Rs767.70 on the BSE.
The scrip opened at Rs765.80 and has touched a high and low of Rs773.60 and Rs765.80, respectively. So far, 3,89,422 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs34,734.72cr.